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INTRODUCTION
Facioscapulohumeral muscular dystrophy (FSHD; MIM
158900) is a neuromuscular disorder with an autosomal
dominant pattern of inheritance and the incidence of this
disease is estimated to be 1/20,000 in the European popula-
tion (1). In most cases, the clinical phenotype has been known
to be distinctive. Facial weakness, winged scapulae, horizon-
tally placed clavicles, humeral and brachioradialis muscle
atrophy, proximal limb weakness, and asymmetry in muscle
involvement are found to some degree in most affected indi-
viduals (1).
In 1992, Wijmenga et al. revealed that FSHD is due to
deletions of integral copies of a 3.2 kb tandemly repeated
D4Z4 units at the 4q35 locus (2). In 95% of patients with
FSHD, the D4Z4 repeat is contracted to an array of 1-10
units, and, apparently, at least one unit of D4Z4 is required
to develop FSHD (2, 3). There is a rough and inverse rela-
tionship between clinical severity and the residual repeat
size, with the smallest repeats causing the most severe phe-
notypes (4, 5).
With the aid of genetic testing, the clinical phenotype has
expanded to include asymptomatic gene carriers, facial-spar-
ing scapular myopathy, proximal weakness without scapular
winging, and distal myopathy (6-11). Intrafamilial clinical
variability is a common feature in FSHD (12). Symptoms
usually commence in the second or third decade for most
affected patients (13).
Although FSHD is the second most common muscular
dystrophy after myotonic dystrophy 1 in adulthood and the
incidence of this disease in Korean population might not be
different from Europeans, there were only few reports on
Korean patients with FSHD (13-15). In the present study,
we performed a genetic study of Korean patients with clini-
cal features resembling FSHD. In addition, we investigated
the correlation between the severity of clinical features and
that of genetic abnormalities.
MATERIALS AND METHODS
Four unrelated patients with clinical features of FSHD
were clinically and genetically evaluated. To assess the clini-
cal severity, we adopted Clinical Severity Scale based upon
the extent of weakness in various muscular parts (16). With
informed consent, genomic DNA was extracted from periph-
eral blood leukocytes. In order to determine the number of
D4Z4 repeats on 4q35, we performed conventional South-
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Clinical and Genetic Analysis of Korean Patients with 
Facioscapulohumeral Muscular Dystrophy
Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal dominantly inher-
ited muscular disorder, which is characterized by weakness of facial, shoulder and
hip girdle, humeral, and anterior distal leg muscles. The FSHD gene has been
mapped to 4q35 and a deletion of integral copies of a 3.3-kb DNA repeat motif
named D4Z4 was known to be the genetic background of the disorder. Although
FSHD is the second most common muscular dystrophy in adulthood, there were
few reports on the genetically confirmed patients in Korea. Recently, we experi-
enced four Korean patients with clinical features resembling FSHD. In order to
confirm the diagnosis, conventional Southern blot (SB) analysis by using double
digestion with EcoRI and BlnI and hybridization with p13E-11 probe was performed
in three patients and newly developed long polymerase chain reaction (PCR) method
was used for one patient because genomic DNA was not enough for conventional
SB for this patient. All patients were demonstrated to have shortened D4Z4 repeats
that were consistent with FSHD. Therefore, we could confirm the diagnosis of FSHD
in four Korean patients and appropriate genetic counseling was done for the patients
and their families. It is of note that long-PCR method could be a good alternative
for conventional SB when D4Z4 repeats were less than 5.
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Accepted : 16 February 2008ern blot analysis or long-polymerase chain reaction (PCR) as
described previously (17). For Southern blot analysis, EcoRI
or EcoRI/BlnI digested genomic DNA was separated by gel
electrophoresis and then the DNA was transferred to Hy-
bond XL (Amersham Biosciences, Piscataway, NJ, U.S.A.).
After hybridization with radioisotope labeled p13E-11 equiv-
alent PCR probe, the EcoRI and EcoRI/BlnI allele sizes were
analyzed (18). Long-PCR detection of shortened D4Z4 re-
peats was performed for patient 3 because the genomic DNA
was not enough for conventional Southern blot analysis. All
conditions and primer sequences for long-PCR was described
previously and a positive control with 2 D4Z4 repeats and a
negative control were tested in parallel (19). 
RESULTS
Clinical findings
Patient 1 was a 30-yr-old woman complaining of progres-
sive limb muscle weakness. She was in good health until
age 12 yr, at which time she began to have a difficulty in
raising her right arm above her head. Later, she developed
increasing difficulties climbing stairs. By report, her mother
had similar symptoms from the age of 40. His 35-yr-old
brother was not affected clinically (Fig. 1A). The neurologi-
cal examination was remarkable for moderate facial weak-
ness; moderate (Medical Research Council [MRC] grade 3)
and mild (MRC grade 4) weakness of proximal upper and
lower limb muscles, respectively; humeral atrophy; anterior
axillary folds; winged scapulae; waddling gait; and hypoac-
tive deep tendon reflexes. The serum creatine kinase (CK)
was 233 IU/L (normal, <270 IU/L). Other routine laborato-
ry tests including thyroid and parathyroid function were nor-
mal. Audiogram, electrocardiogram, echocardiogram, nerve
conduction studies were unremarkable. Needle electromyo-
graphy showed chronic myopathic changes in the left del-
toid, biceps brachii, and vastus lateralis muscles. A muscle
biopsy from the right vastus lateralis revealed marked fiber
size variations, increased internalized nuclei, endomyseal fibro-
sis and fat ingrowth, and frequent lobulated myofibers.
Patient 2 was a 36-yr-old man presenting with progres-
sive limb muscle weakness, which developed at the age of
20. Initially, he began to have a difficulty in raising his arm
above his head and climbing stairs. The weakness was slow-
ly progressive. His mother was noted to have similar symp-
toms (Fig. 1B). His 34-yr-old brother and 39-yr-old sister
were not affected clinically. The neurological examination
was remarkable for moderate facial weakness; mild (MRC
grade 4) and minimal weakness of proximal and distal ex-
tremity muscles, respectively; and humeral and quadriceps
atrophy. Other remarkable findings included winged scapu-
lae, anterior axillary folds, waddling gait, and hypoactive
deep tendon reflexes. The serum creatinine kinase (CK) was
610 IU/L. The forced vital capacity (FVC) was 3.2 L (71%
of predicted). Electrocardiogram, echocardiogram, audio-
gram, and nerve conduction studies were normal. Needle
electromyography demonstrated chronic myopathic changes. 
Patient 3 was an 18-yr-old man complaining of progres-
sive right upper limb weakness over the prior 3 yr. The ini-
tial diagnosis was idiopathic right brachial plexopathy. He
was a tennis player in his early teens. There was no family
history of neuromuscular disease (Fig. 1C). Clinical exami-
nation of his parents was normal. Remarkable neurological
findings included mild bifacial weakness; mild (MRC grade
4) and minimal weakness of the right and left proximal upper










Fig. 1. Pedigrees of 4 patients with FSHD. Circle, female; square, male; black symbol, affected with shortened D4Z4 repeats; gray sym-
bol, possibly affected by history; arrow, proband; N, tested for D4Z4 repeats and found normal.
Nlimb muscles, respectively; winged scapulae in the right side;
and hypoactive deep tendon reflexes. The serum CK was 750
IU/L. Other routine laboratory tests including thyroid func-
tion were normal. Audiogram, electrocardiogram, echocar-
diogram, and nerve conduction studies were unremarkable.
The FVC was 4.2 L (98% of predicted). Needle electromyo-
graphy revealed chronic myopathic changes.
Patient 4 was a 46-yr-old man presenting with progres-
sive limb muscle weakness developed in his early twenties.
He first noticed a difficulty in raising his arm above his head.
There was no known family history of neuromuscular dis-
ease in his parents, five sibs, and two daughters (Fig. 1D).
The neurological examination was remarkable for mild (MRC
grade 4) weakness of proximal upper limb muscles and humer-
al atrophy. Other remarkable findings included anterior axil-
lary folds, asymmetric winged scapulae, trapezius hump sign,
Beevor’s sign, and hypoactive deep tendon reflexes. There
was no facial weakness. The serum CK was 170 IU/L. The
FVC was 4.19 L (87% of predicted). Electrocardiogram,
echocardiogram, and nerve conduction studies were normal.
Needle electromyography showed chronic myopathic changes.
Genetic analysis and genotype-phenotype correlations
All four patients were demonstrated to have shortened
D4Z4 repeats. Patients 1, 3, and 4 had 4, 6, and 7 repeats
of D4Z4 segment confirmed by conventional Southern blot,
respectively (Fig. 2). Patient 2 was tested by long-PCR that
he had 3 D4Z4 repeats (Fig. 3). When we tested both par-
ents of the patient 3, they did not have shortened D4Z4
repeats suggesting a de novo mutation occurred in patient
3. Since the mothers of patients 1 and 2 were not tested genet-
ically, we could not confirm the inheritance of pathogenic
D4Z4 repeats in these families.
In the four patients in our study, the tendency of inverse
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Fig. 2. Representative results of Southern blot analysis. Convential
electrophoresis and Southern blot analysis of EcoRI (E) and EcoRI/
BlnI (E/B) digested DNA from patient 4 and his father revealed a
28-kb sized EcoRI fragment (*) resistant to BlnI digestion only in
patient 4. Another EcoRI framgenet between 38 kb and 48 kb
disappeared after BlnI digestion (#). 
M1, 1-kb size marker; M2, high molecular weight size marker.
Fig. 3. Result of long-PCR amplification in patient 2. A 18.4 kb
PCR product (*) corresponding to 3 D4Z4 repeats was detected
in patient 2 (lane 1) while a 11.8 kb sized band (#) was noticed in
positive control (P) with 2 D4Z4 repeats. No band was observed
in the patient’s brother (lane 2) and in negative control (N). 
M, high molecular weight size marker.













*, Clinical severity scale by Ricci et al. 1999.








1 12 3.5 4
2 20 3.0 3
3 15 1.5 6
4 20 1.5 7
Table 1. Clinical features of the patients with FSHD in relation to
D4Z4 repeat number





*correlation between clinical severity and D4Z4 repeat num-
ber was suggested. However, similar tendency was not found
between age of onset and D4Z4 repeat number (Table 1).
DISCUSSION
To date, the diagnosis of FSHD was usually made on the
basis of clinical findings in Korea. Although individual pa-
tients with FSHD may vary to some extent, most of the pa-
tients fit into a clinically typical feature. However, with the
availability of genetic testing, it has been recently reported
that the clinical manifestations of FSHD are much broader
than previously known (6-11). Therefore, it can be mislead-
ing to make a diagnosis solely based on the clinical findings
especially in the patient with atypical presentations. In our
study, two patients showed unusual clinical features. The
initial diagnosis of patient 3 was idiopathic brachial plex-
opathy due to right arm weakness, asymmetric winged scapu-
lae, and a negative family history. In patient 4, facial weak-
ness and family history were absent. Furthermore, other tests
including serum CK, needle electromyography, and muscle
biopsy often do not helpful in the diagnosis of FSHD, as in
our patients. Therefore, genetic testing is essential to confirm
the correct diagnosis of FSHD. And it will be also helpful
to facilitate the diagnosis and avoid unnecessary tests, espe-
cially in the patient with atypical presentations.
Molecular diagnosis for FSHD is used for diagnostic con-
firmation, pre-symptomatic testing, and for prenatal diagno-
sis. FSHD diagnosis relies on the detection of a D4Z4 repeat
array less than 35 kb (<10 units) (20). However, a number
of factors have complicated the molecular diagnosis of FSHD
(13). First, it was reported that a highly homologous and
equally polymorphic repeat resides on chromosome 10. Sec-
ond, in nearly one-fifth of all individuals, exchanges of repeat
units have been observed between chromosomes 4 and 10.
A third complication comes from the observation of a bi-
allelic variation of chromosome 4qter, designated 4qA and
4qB. It is reported that FSHD is associated solely with the
4qA allele and contractions of D4Z4 on 4qB subtelomeres
do not cause FSHD (21, 22). Furthermore, a minority of
patients carries a contraction of D4Z4 that extends in a proxi-
mal direction. The disease allele in these patients often goes
undetected, as the probe region is also missing from the dis-
ease allele. Lastly, locus heterogeneity still remains. Nonethe-
less, Southern blot analysis using two restriction enzymes
discriminating 4-type and 10-type units are very useful that
FSHD can be diagnosed with up to 98% accuracy (23).
Recently, a new diagnostic method for rapid and specific
diagnosis of FSHD by a long PCR has been introduced (19).
This long PCR method can specifically amplify the repeat-
ed region from chromosome 4q up to 18.4 Kb in size and
countable from one to five D4Z4 repeated units. By using
this new technique, we can confirm a diagnosis of FSHD in
one patient in whom we could not perform conventional
Southern blot analysis due to insufficient DNA. Although
Lemmers et al. (24) argued that at least half of the Caucasian
FSHD patients could not be diagnosed by the long PCR
method because of the different distribution of D4Z4 repeats
alleles in Japanese and in Caucasians, this method might be
useful when the conventional Southern blot analysis is unavail-
able. Nevertheless, careful attention should be made to pre-
vent false-negative results by long PCR method because of
amplification failure due to 5 or more D4Z4 repeats.
Penetrance of FSHD was found variable by age and gen-
der that it was 83% by age 30 yr and males were reported
to be more severely and more frequently affected than females
(95% vs. 69%, respectively) (25). Anticipation in FSHD
remains controversial, but an inverse correlation between
D4Z4 repeat size and the clinical severity and onset age was
reported (4, 5). A similar result was suggested only in the
clinical severity in our study. However, the number of the
patients in our study was too limited to clearly verify a rela-
tionship between the clinical features and D4Z4 repeat size.
Further study in a larger number of the FSHD patients is
needed.
This study reports four patients with genetically estab-
lished FSHD. Two of them had family histories while the
others did not. Considering that genomic structure of D4Z4
repeat in chromosomes 4 and 10 in Koreans is similar to that
in Japanese, the frequency of FSHD might not be different
from that in Japan (26). However, there are only limited
reports on the FSHD in Korea (14, 15). Therefore, more
efforts should be made to identify and to diagnose Korean
patients with FSHD by genetic analysis.
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